{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:17:37Z","timestamp":1789186657615,"version":"build-2803163510"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:p>\n                    <jats:bold>SETTING:<\/jats:bold>\n                    Studies have shown that linezolid (LZD) can be used to treat extensively drug-resistant tuberculosis (XDR-TB).\n                    <jats:bold>OBJECTIVE:<\/jats:bold>\n                    To conduct a systematic review and meta-analysis to assess existing evidence concerning efficacy and safety of LZD for XDR-TB treatment.\n                    <jats:bold>DESIGN:<\/jats:bold>\n                    The MEDLINE@OVID, PubMed, EMBASE, the Cochrane Library, Clinical Trials, Sinomed, CMCI, CNKI, VIP and Wanfang databases were systematically searched for randomised controlled trials, cohort studies, case series or case reports on XDR-TB patients treated with LZD from January 2000 to December\n 2016. Summary estimates of the rate of sputum culture conversion, treatment success and adverse effects were calculated; data that could not be combined were summarised and described qualitatively. The combined results were examined for heterogeneity, sensitivity and publishing bias.\n                    <jats:bold>RESULTS:<\/jats:bold>\n                    Twenty-two original studies covering a total of 302 patients with XDR-TB fulfilled the inclusion criteria. Pooled estimates for sputum culture conversion and treatment success rates were respectively 93.2% and 67.4% in XDR-TB patients on LZD treatment. The pooled estimates for the rate of\n myelosuppression, peripheral neuropathy, optic neuritis and adverse reactions of the gastrointestinal tract were respectively 42.5%, 26.0%, 19.0% and 35.0%. Heterogeneity was mostly due to the initial dose of LZD (\u2264600 mg\/d or &gt;600 mg\/d), as patients with a high initial dose of LZD were\n more likely to have myelosuppression (48.4% vs. 24.8%,\n                    <jats:italic>P<\/jats:italic>\n                    = 0.010) and adverse events of the gastrointestinal tract (41.3% vs.15.4%,\n                    <jats:italic>P<\/jats:italic>\n                    = 0.100).\n                    <jats:bold>CONCLUSION:<\/jats:bold>\n                    LZD appears to be effective for XDR-TB, but adverse events are common. An LZD dose of \u2264600 mg\/d as the initial\n dose for treating XDR-TB patients is recommended.\n                  <\/jats:p>","DOI":"10.5588\/ijtld.18.0822","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T05:28:49Z","timestamp":1578893329000},"page":"1293-1307","source":"Crossref","is-referenced-by-count":40,"title":["Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis"],"prefix":"10.5588","volume":"23","author":[{"given":"Z.","family":"Lifan","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Centre for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical\n College, Beijing, Clinical Epidemiology Unit, International Epidemiology Network, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Sainan","sequence":"additional","affiliation":[{"name":"Centre for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Siyan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Xiaoqing","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Centre for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical\n College, Beijing, Clinical Epidemiology Unit, International Epidemiology Network, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2019\/00000023\/00000012\/art00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T23:33:28Z","timestamp":1615419208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.18.0822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":0,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12,1]]}},"alternative-id":["1027-3719(20191201)23:12L.1293;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.18.0822","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737311545.793570587","asserted-by":"object"}]},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}